Much progress has been made over the last 30 years in the HIV/AIDS arena. HIV infection is no longer considered a death sentence, thanks to antitretroviral “cocktail” medications. Experts say the biggest advance over the last three decades has been these agents, which have been able to stop the replication of the virus. This, they say, has transformed what was once a fatal disease to more of a chronic illness.
Daria Hazuda, Ph.D., VP and worldwide discovery head of infectious diseases franchise at Merck Research Laboratories, says the development of combination antiretroviral…
30 Years of Progress: HIV/AIDS Medication Facts
Stephen J. Brown, M.D. VP, Medical Director, AIDS Research Alliance, an independent, nonprofit research institute. For more information, visit aidsresearch.org.
Awny Farajallah. Executive Director, Atazanavir Development, Bristol-Myers Squibb Co., a biopharmaceutical company committed to discovering, developing, and delivering innovative medicines. For more information, visit bms.com.
George Hanna, M.D. VP, HIV Development, Bristol-Myers Squibb Co., a biopharmaceutical company committed to discovering, developing, and delivering innovative medicines. For more information, visit bms.com.
Daria Hazuda, Ph.D. VP and Worldwide Discovery Head of Infectious Diseases Franchise, Merck Research Laboratories, the research division of Merck & Co. Inc. For more information, visit merck.com/mrl.
Robert T. McNally, Ph.D. President and CEO, GeoVax Labs Inc., a biotechnology company developing human vaccines for HIV and AIDS. For more information, visit geovax.com.
Elisha Talley-Roithner. Executive Director, Project Management, and Global Therapeutic Area Head for Infectious Diseases, PPD Inc., a CRO providing drug discovery, development, and life cycle management services. For more information, visit ppdi.com.